HRTX on Nasdaq
HERON THERAPEUTICS, INC. /DE/
In its 2026 annual report the company says: “We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.”4 It is headquartered in San Diego, United States.2 Its shares trade on Nasdaq under the symbol HRTX.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Liquidia Corporation, MACROGENICS INC or ELITE PHARMACEUTICALS INC /NV/, or pick any stock.
- TickerHRTX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersSan Diego, United States2
- Incorporated inDE3
- Business address4242 Campus Point Court, Suite 200, San Diego, Ca 921213
- Filer categoryAccelerated filer3
- Legal formCorporation2
- LEI549300DR2I1DOPD2IX532
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O UNITED STATES CORPORATION COMPANY, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 21168012
See how the biggest companies compare on our leaderboards
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
73.3%Gross margin5
-1.6%Operating margin5
-13.0%Net margin5
7.4%Revenue growth, 20255
-140.9%Return on equity5
-$27.9MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Cinvanti brought in 62% of the revenue HERON THERAPEUTICS, INC. /DE/ broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cinvanti | $94.9M | $100.1M | $96.8M |
| Zynrelef | $17.7M | $25.5M | $38.1M |
| Aponvie | $1.4M | $4.5M | $11.6M |
| Sustol | $13.1M | $14.1M | $8.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$41.3M
- Research and development8¢$12.4M
- Other costs65¢$101.1M
Out of $154.9M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net product sales | $154.9M | $144.3M | $127.0M |
| Cost of product sales | $41.3M | $38.6M | $65.1M |
| Gross profit | $113.6M | $105.6M | $61.9M |
| Research and development | $12.4M | $16.7M | $39.1M |
| General and administrative | $54.6M | $53.4M | $65.8M |
| Sales and marketing | $49.1M | $47.1M | $67.6M |
| Total operating expenses | $116.1M | $117.2M | $172.6M |
| Loss from operations | -$2.5M | -$11.5M | -$110.6M |
| Interest income | $1.9M | $3.5M | $3.4M |
| Interest expense | -$9.6M | -$6.0M | -$3.9M |
| Loss on debt extinguishment | -$11.3M | ||
| Other income | $1.3M | $430.0K | $560.0K |
| Total other (expense) income, net | -$17.7M | -$2.1M | $56.0K |
| Net loss | -$20.2M | -$13.6M | -$110.6M |
| Unrealized (losses) gains on short-term investments | -$9.0K | $32.0K | |
| Comprehensive loss | -$20.2M | -$13.6M | -$110.5M |
| Basic net loss per share | -$0.12 | -$0.09 | -$0.80 |
| Shares used in computing basic net loss per share | 166.7M shares | 152.4M shares | 138.1M shares |
| Diluted net loss per share | -$0.12 | -$0.09 | -$0.80 |
| Shares used in computing diluted net loss per share | 166.7M shares | 152.4M shares | 138.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.6M | $25.8M | ||
| Short-term investments | $18.0M | $33.5M | ||
| Accounts receivable, net | $89.6M | $78.9M | ||
| Inventory, net | $92.7M | $53.2M | ||
| Prepaid expenses and other current assets | $9.1M | $17.7M | ||
| Total current assets | $238.1M | $209.0M | ||
| Property and equipment, net | $12.4M | $14.9M | ||
| Right-of-use lease assets | $0 | $2.8M | ||
| Other assets | $5.4M | $6.5M | ||
| Total assets | $255.9M | $233.1M | ||
| Accounts payable | $9.0M | $11.7M | ||
| Accrued clinical and manufacturing liabilities | $26.6M | $25.4M | ||
| Accrued payroll and employee liabilities | $9.3M | $9.6M | ||
| Other accrued liabilities | $51.2M | $41.8M | ||
| Current lease liabilities | $0 | $3.0M | ||
| Total current liabilities | $96.1M | $91.5M | ||
| Non-current notes payable, net | $107.9M | $25.0M | ||
| Non-current convertible notes payable, net | $32.7M | $149.7M | ||
| Other non-current liabilities | $4.8M | $615.0K | ||
| Total liabilities | $241.5M | $266.8M | ||
| Common stock, $0.01 par value: 400,000,000 shares authorized; 188,314,430 shares issued and outstanding at December 31, 2025 and 152,127,878 shares issued and outstanding at December 31, 2024 | $1.9M | $1.5M | ||
| Series A convertible preferred stock, $0.01 par value: 2,500,000 shares authorized; 70,012 shares issued and outstanding at December 31, 2025 and no shares issued and outstanding at December 31, 2024 | $1.1M | $0 | ||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated other comprehensive income | $4.0K | $13.0K | ||
| Accumulated deficit | -$1.9B | -$1.9B | ||
| Total stockholders' equity (deficit) | $14.3M | -$33.7M | -$34.0M | $13.6M |
| Total liabilities and stockholders' equity (deficit) | $255.9M | $233.1M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued (in shares) | 188.3M shares | 152.1M shares | ||
| Common stock, shares outstanding (in shares) | 188.3M shares | 152.1M shares | ||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.5M shares | 2.5M shares | ||
| Preferred stock, shares issued (in shares) | 70.0K shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 70.0K shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.6M | $25.8M | ||
| Short-term investments | $18.0M | $33.5M | ||
| Accounts receivable, net | $89.6M | $78.9M | ||
| Inventory, net | $92.7M | $53.2M | ||
| Prepaid expenses and other current assets | $9.1M | $17.7M | ||
| Total current assets | $238.1M | $209.0M | ||
| Property and equipment, net | $12.4M | $14.9M | ||
| Right-of-use lease assets | $0 | $2.8M | ||
| Other assets | $5.4M | $6.5M | ||
| Total assets | $255.9M | $233.1M | ||
| Accounts payable | $9.0M | $11.7M | ||
| Accrued clinical and manufacturing liabilities | $26.6M | $25.4M | ||
| Accrued payroll and employee liabilities | $9.3M | $9.6M | ||
| Other accrued liabilities | $51.2M | $41.8M | ||
| Current lease liabilities | $0 | $3.0M | ||
| Total current liabilities | $96.1M | $91.5M | ||
| Non-current notes payable, net | $107.9M | $25.0M | ||
| Non-current convertible notes payable, net | $32.7M | $149.7M | ||
| Other non-current liabilities | $4.8M | $615.0K | ||
| Total liabilities | $241.5M | $266.8M | ||
| Common stock, $0.01 par value: 400,000,000 shares authorized; 188,314,430 shares issued and outstanding at December 31, 2025 and 152,127,878 shares issued and outstanding at December 31, 2024 | $1.9M | $1.5M | ||
| Series A convertible preferred stock, $0.01 par value: 2,500,000 shares authorized; 70,012 shares issued and outstanding at December 31, 2025 and no shares issued and outstanding at December 31, 2024 | $1.1M | $0 | ||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated other comprehensive income | $4.0K | $13.0K | ||
| Accumulated deficit | -$1.9B | -$1.9B | ||
| Total stockholders' equity (deficit) | $14.3M | -$33.7M | -$34.0M | $13.6M |
| Total liabilities and stockholders' equity (deficit) | $255.9M | $233.1M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | ||
| Common stock, shares issued (in shares) | 188.3M shares | 152.1M shares | ||
| Common stock, shares outstanding (in shares) | 188.3M shares | 152.1M shares | ||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 2.5M shares | 2.5M shares | ||
| Preferred stock, shares issued (in shares) | 70.0K shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 70.0K shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$20.2M | -$13.6M | -$110.6M |
| Stock-based compensation expense | $10.3M | $13.0M | $32.9M |
| Depreciation and amortization | $2.3M | $2.5M | $2.9M |
| Amortization of debt discount | $744.0K | $751.0K | $133.0K |
| Amortization of debt issuance costs | $73.0K | $210.0K | $206.0K |
| Accretion of discount on short-term investments | -$739.0K | -$2.1M | -$1.7M |
| Retirement and impairment of property and equipment | $414.0K | $4.4M | $617.0K |
| (Gain)/Loss on disposal of property and equipment | -$27.0K | $10.0K | |
| Loss on extinguishment of debt | $11.3M | ||
| Accounts receivable | -$10.7M | -$18.7M | -$8.1M |
| Inventory | -$31.1M | -$11.1M | $12.5M |
| Prepaid expenses and other assets | $878.0K | -$9.9M | $15.4M |
| Accounts payable | -$2.7M | $8.5M | $15.0K |
| Accrued clinical and manufacturing liabilities | $1.4M | $3.2M | -$2.2M |
| Accrued payroll and employee liabilities | -$284.0K | $330.0K | -$4.2M |
| Other accrued liabilities | $10.6M | $99.0K | $3.3M |
| Net cash used in operating activities | -$27.6M | -$22.5M | -$58.8M |
| Purchases of short-term investments | -$50.8M | -$103.1M | -$87.7M |
| Maturities and sales of short-term investments | $67.0M | $123.5M | $107.2M |
| Purchases of property and equipment | -$317.0K | -$1.7M | -$1.5M |
| Proceeds from the sale of property and equipment | $98.0K | $27.0K | $13.0K |
| Net cash provided by investing activities | $16.0M | $18.7M | $18.0M |
| Net proceeds from the sale of common stock | $18.3M | $29.8M | |
| Proceeds from sale of Series A Convertible Preferred Stock | $7.9M | ||
| Cash paid for convertible notes extinguishment | -$125.0M | ||
| Cash paid for notes extinguishment | -$25.0M | ||
| Net proceeds from convertible note issuance | $31.9M | ||
| Net proceeds from notes issuance | $105.4M | $24.4M | |
| Proceeds from warrant exercises | $1.0K | ||
| Proceeds from purchases under the Employee Stock Purchase Plan | $853.0K | $637.0K | $904.0K |
| Receipts (payments) for stock issued under the equity incentive plan | $160.0K | $303.0K | -$903.0K |
| Net cash provided by financing activities | $14.4M | $940.0K | $54.1M |
| Net increase (decrease) in cash and cash equivalents | $2.8M | -$2.9M | $13.3M |
| Interest paid | $6.5M | $4.9M | $3.1M |
No quarter-by-quarter statement was filed.
Corporate structure
HERON THERAPEUTICS, INC. /DE/ sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of HERON THERAPEUTICS, INC. /DE/
- Adage Capital Management, L.P. Filed SCHEDULE 13G/A on HERON THERAPEUTICS, INC. /DE/, latest May 13, 2026 (2 filings since Nov 12, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- Clearline Capital LP Filed SCHEDULE 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 17, 2026 (2 filings since Nov 26, 2025)
- Rubric Capital Management LP Filed SCHEDULE 13D/A on HERON THERAPEUTICS, INC. /DE/, latest Oct 17, 2025 (6 filings since Feb 6, 2023)
- BlackRock Filed SC 13G on HERON THERAPEUTICS, INC. /DE/, latest Nov 8, 2024 (5 filings since Feb 1, 2022)
- BAKER BROS. ADVISORS LP Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 14, 2024 (2 filings since Feb 14, 2022)
- Deep Track Capital, LP Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 14, 2024 (2 filings since Aug 19, 2022)
- GREAT POINT PARTNERS LLC Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 14, 2024 (2 filings since Apr 13, 2023)
- Franklin Templeton Investments Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 6, 2024 (3 filings since Feb 3, 2022)
- JPMorgan Chase Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Dec 7, 2023 (3 filings since Jan 24, 2022)
- ArrowMark Colorado Holdings LLC Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 15, 2023 (2 filings since Feb 14, 2022)
- TANG CAPITAL PARTNERS LP Filed SC 13G/A on HERON THERAPEUTICS, INC. /DE/, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- HERON THERAPEUTICS, INC. /DE/ San Diego, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What HERON THERAPEUTICS, INC. /DE/ reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Construction in progress | $1.7M5 Dec 31, 2025 | $2.6M5 Dec 31, 2024 | −34.6% |
| Property and equipment, before depreciation | $25.3M5 Dec 31, 2025 | $32.7M5 Dec 31, 2024 | −22.7% |
| Accumulated depreciation | $12.9M5 Dec 31, 2025 | $17.8M5 Dec 31, 2024 | −27.8% |
| Property and equipment, net | $12.4M5 Dec 31, 2025 | $14.9M5 Dec 31, 2024 | −16.6% |
| Operating-lease assets (leased space) | $05 Dec 31, 2025 | $2.8M5 Dec 31, 2024 | −100.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $28.6M5 Dec 31, 2025 | $25.8M5 Dec 31, 2024 | +11.0% |
| Marketable securities, current | $18.0M5 Dec 31, 2025 | $33.5M5 Dec 31, 2024 | −46.3% |
| Debt securities available for sale | $18.0M5 Dec 31, 2025 | $33.5M5 Dec 31, 2024 | −46.3% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $92.7M5 Dec 31, 2025 | $53.2M5 Dec 31, 2024 | +74.5% |
| Raw materials | $59.2M5 Dec 31, 2025 | $19.7M5 Dec 31, 2024 | +200.3% |
| Work in process | $26.6M5 Dec 31, 2025 | $27.2M5 Dec 31, 2024 | −2.1% |
| Finished goods | $6.9M5 Dec 31, 2025 | $6.2M5 Dec 31, 2024 | +10.4% |
Properties, in its own words
We have an operating lease for 52,148 square feet of laboratory and office space in San Diego, California, which expired on December 31, 2025. In October 2021, we entered into a sublease agreement to sublet 23,873 square feet of laboratory and office space in San Diego, California. The space was delivered to the subtenant in March 2022. As a result of the sublease agreement, our one five-year option to renew this lease on expiration applied only with respect to our remaining 28,275 square feet of laboratory and office space.
We have a short-term operating lease for 9,882 square feet of office space in Cary, North Carolina, which was entered into in December 2025 and will expire on February 28, 2026.
The rest of Item 2
In August 2025, we entered into a lease agreement for 16,837 square feet of office space in Cary, North Carolina, with the lease term expected to commence no later than May 25, 2026 ("lease commencement date") and expire 111 months from the lease commencement date, with the option to extend for one additional period of 84 months upon written notice.
Item 2 of the 10-K filed Feb 26, 2026.4
Leadership
Who has led HERON THERAPEUTICS, INC. /DE/, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerCraig A. Collard Apr 5, 2023 to now13
- Chief executive officerBarry D. Quart May 3, 2013 to Jan 20, 202314
- Chief executive officerJohn Whelan Jul 12, 2011 to Feb 12, 201315
- Chief executive officerRonald J. Prentki Jul 9, 2008 to Feb 19, 201016
- Chief executive officerMichael Oconnell Jan 12, 2006 to Jan 12, 200617
- Chief executive officerGreg Turnbull Oct 10, 2006 to May 30, 200818
- PresidentBarry D. Quart Feb 14, 2020 to Feb 14, 202019
- PresidentJohn Poyhonen Oct 15, 2020 to Apr 17, 202320
- PresidentJohn Whelan Jul 12, 2011 to Feb 12, 201315
- PresidentRonald J. Prentki Jul 9, 2008 to Feb 19, 201016
- PresidentGreg Turnbull Oct 10, 2006 to May 30, 200818
- Chief financial officerIra Duarte Jun 23, 2023 to now21
- Chief financial officerRobert Hoffman Apr 24, 2017 to Dec 23, 201922
- Chief financial officerBrian G. Drazba Nov 1, 2013 to Dec 23, 201623
- Chief financial officerJohn Whelan Feb 25, 2009 to Jul 19, 201324
- Chief financial officerGreg Turnbull May 30, 2008 to Oct 1, 200825
- Chief financial officerStephen Whiteford Sep 28, 2006 to Dec 18, 200626
- Chief operating officerMark Earl Hensley Apr 29, 2025 to now27
- Chief operating officerDavid Leslie Szekeres Oct 20, 2020 to Jul 17, 202328
- Chief operating officerMichael A. Adam Jul 12, 2011 to Feb 12, 201329
Board members and other officers (30)
- EVP, Chief Development OfficerWilliam P. Forbes Jun 12, 2023 to now30
- VP, Chief Accounting OfficerLisa Peraza Oct 15, 2020 to Jan 19, 202431
- EVP, Chief Commercial OfficerJohn Poyhonen Jul 17, 2019 to Dec 23, 201932
- Executive VP, Drug DevelopmentKimberly Manhard Jan 29, 2016 to Apr 17, 202333
- SVP & Chief Medical OfficerNeil James Clendeninn Oct 13, 2015 to Oct 13, 201534
- SVP & Chief Medical OfficerMark S. Gelder Md. Dec 13, 2012 to Dec 15, 201435
- V. P. of Clinical DevelopmentAnastassios D. Retzios Nov 20, 2006 to Jan 17, 200836
- Board memberThomas Cusack Nov 7, 2025 to now37
- Board memberMichael Kaseta Nov 5, 2024 to now38
- Board memberAdam Morgan Feb 24, 2023 to now39
- Board memberCraig A. Collard Mar 2, 2023 to now40
- Board memberKevin Kotler Mar 2, 2023 to Mar 2, 202341
- Board memberSharmila Dissanaike Sep 29, 2021 to now42
- Board memberSusan Rodriguez Sep 29, 2021 to Feb 4, 202543
- Board memberWaage Christian Jun 23, 2016 to now44
- Board memberCraig A. Johnson Jan 15, 2014 to now45
- Board memberKimberly Manhard Jan 15, 2014 to Jan 20, 202346
- Board memberJohn Poyhonen Jan 21, 2014 to Dec 23, 201947
- Board memberBarry D. Quart Jun 20, 2012 to Jan 20, 202348
- Board memberJohn Whelan Jul 12, 2011 to Feb 12, 201315
- Board memberKevin C. Tang Oct 21, 2009 to Feb 14, 202049
- Board memberRonald J. Prentki Jul 9, 2008 to Feb 19, 201016
- Board memberDennis L. Winger Mar 20, 2006 to Aug 14, 200650
- Board memberGreg Turnbull Mar 20, 2006 to May 31, 201251
- Board memberPeter Riepenhausen Mar 20, 2006 to May 30, 200852
- Board memberRobert L. Zerbe Md. Mar 20, 2006 to May 26, 201053
- Board memberStephen A. Drury Mar 20, 2006 to Aug 14, 200654
- Board memberToby Rosenblatt Mar 20, 2006 to May 26, 201055
- Board memberPaul Goddard Apr 19, 2006 to May 26, 201056
- Board memberArthur T. Taylor Aug 15, 2006 to May 30, 200857
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorChristian Waage named Aug 1, 202358
Former names
Timeline
- Sep 29, 20268-K Entered a material agreement59
- Aug 14, 20268-K Entered a material agreement; Change to shareholders' rights60
- Aug 10, 20268-K Results of operations61
- Jun 25, 20268-K Listing notice or transfer62
- Jun 16, 20268-K Shareholder vote63
- Jun 2, 20268-K Other events64
- May 11, 20268-K Results of operations65
- Apr 6, 20268-K Executive or director change66
- Feb 26, 20268-K Results of operations67
- Jan 9, 20268-K Regulation FD disclosure68
- Nov 4, 20258-K Results of operations69
- Oct 29, 20258-K Executive or director change; Regulation FD disclosure70
- Apr 5, 2023New chief executive Craig A. Collard becomes CEO13
- May 3, 2013New chief executive Barry D. Quart becomes CEO14
- Jul 12, 2011New chief executive John Whelan becomes CEO15
- Jul 9, 2008New chief executive Ronald J. Prentki becomes CEO16
- Oct 10, 2006New chief executive Greg Turnbull becomes CEO18
- Jan 12, 2006New chief executive Michael Oconnell becomes CEO17
- Feb 5, 1987Founded HERON THERAPEUTICS, INC. /DE/ is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.05) a share, on Nov 4, 2025.71
When it reported results
- Aug 10, 2026Reported quarterly or annual results61
- May 11, 2026Reported quarterly or annual results65
- Feb 26, 2026Reported quarterly or annual results67
- Nov 4, 2025Reported quarterly or annual results69
- Aug 8, 2025Reported quarterly or annual results72
- May 6, 2025Reported quarterly or annual results73
- Feb 27, 2025Reported quarterly or annual results74
- Nov 12, 2024Reported quarterly or annual results75
Drug trials and FDA: recently
- Oct 25, 2021Phase 3 trial completed Phase 3 trial of HTX-011, Ibuprofen and others in Analgesia: primary completion Oct 25, 2021, results posted Jun 4, 2026 (ClinicalTrials.gov NCT03907176).76
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
353 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 181 insider forms, 43 large holders, 1 private raises, 40 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Aug 14, 20268-K EDGAR
- Aug 10, 20264 EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jun 25, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 16, 20268-K EDGAR
- Jun 8, 20264 EDGAR
- Jun 2, 20268-K EDGAR
- May 13, 2026SCHEDULE 13G/A EDGAR
- May 11, 202610-Q EDGAR
- May 11, 20268-K EDGAR
The 353 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
10 open-market trades by officers, directors and large owners since October 2021: 7 buys and 3 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | Morgan AdamDirector | Buy | 1,766,546 | $1.50 | $2.6M | Form 4 |
| Aug 8, 2025 | Rosen David Efraim10% owner | Buy | 2,387,225 | $1.50 | $3.6M | Form 4 |
| Nov 17, 2023 | Forbes William PEVP, Chief Development Officer | Buy | 25,000 | $1.09 | $27.2K | Form 4 |
| Nov 16, 2023 | Forbes William PEVP, Chief Development Officer | Buy | 50,000 | $0.94 | $47.0K | Form 4 |
| Nov 16, 2023 | Collard Craig AChief Executive Officer | Buy | 150,000 | $0.92 | $138.0K | Form 4 |
| Nov 16, 2023 | Duarte IraEVP, Chief Financial Officer | Buy | 85,000 | $0.89 | $75.7K | Form 4 |
| Jul 21, 2023 | Morgan AdamDirector | Buy | 2,486,744 | $1.37 | $3.4M | Form 4 |
| May 3, 2022 | MANHARD KIMBERLYEVP, Drug Development | Sale | 1,504 | $4.76 | $7.2K | Form 4 |
| Dec 21, 2021 | Christian WaageDirector | Sale | 300 | $9.73 | $2.9K | Form 4 |
| Dec 21, 2021 | Johnson Craig ADirector | Sale | 250 | $9.73 | $2.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Adage Capital Management, L.P.SCHEDULE 13G/A, 2 filings Nov 12, 2024 to May 13, 202677
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202678
- Clearline Capital LPSCHEDULE 13G/A, 2 filings Nov 26, 2025 to Feb 17, 202679
- Rubric Capital Management LPSCHEDULE 13D/A, 6 filings Feb 6, 2023 to Oct 17, 202580
- BlackRockSC 13G, 5 filings Feb 1, 2022 to Nov 8, 202481
- BAKER BROS. ADVISORS LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202482
- Deep Track Capital, LPSC 13G/A, 2 filings Aug 19, 2022 to Feb 14, 202483
- GREAT POINT PARTNERS LLCSC 13G/A, 2 filings Apr 13, 2023 to Feb 14, 202484
- Franklin Templeton InvestmentsSC 13G/A, 3 filings Feb 3, 2022 to Feb 6, 202485
- JPMorgan ChaseSC 13G/A, 3 filings Jan 24, 2022 to Dec 7, 202386
- ArrowMark Colorado Holdings LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 15, 202387
- TANG CAPITAL PARTNERS LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202388
- OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)SC 13G/A, 2 filings Feb 14, 2022 to Feb 13, 202389
- State Street CorporationSC 13G/A, 3 filings Feb 11, 2022 to Jan 10, 202390
- Wellington Management CompanySC 13G/A, 1 filing Feb 4, 202291
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Mark Hensley | 43 | $372.2K | $4.3M92 |
| 2025 | Craig Collard, | 60 | $689.4K | $3.5M92 |
| 2025 | William Forbes | 64 | $609.9K | $1.7M92 |
| 2025 | Ira Duarte | 57 | $559.8K | $1.6M92 |
| 2024 | Chief Executive Officer | $669.5K | $3.4M92 | |
| 2024 | EVPChief Financial Officer | $515.0K | $1.4M92 | |
| 2023 | Chief Executive Officer | $493.0K | $10.8M92 | |
| 2023 | EVPChief Financial Officer | $271.2K | $1.5M92 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $30.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2023 | $30.0M | $30.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Rubric Capital Management LP | 30,046,828 | $12.8M | 0.1% | No change |
| Clearline Capital LP | 11,383,961 | $4.9M | 0.3% | −851,278 |
| BlackRock, Inc. | 10,550,750 | $4.5M | 0.0% | +444,328 |
| Velan Capital Investment Management LP | 8,753,290 | $3.7M | 2.3% | No change |
| Vanguard Capital Management LLC | 7,782,741 | $3.3M | 0.0% | −27,588 |
| Tejara Capital Ltd | 6,510,795 | $2.8M | 1.1% | +174,040 |
| Tang Capital Management LLC | 6,250,000 | $2.7M | 0.1% | No change |
| Geode Capital Management, LLC | 4,270,980 | $1.8M | 0.0% | +260,893 |
| Millennium Management LLC | 4,070,101 | $1.7M | 0.0% | −3,560,426 |
| JW Asset Management, LLC | 3,751,073 | $1.6M | 0.5% | No change |
| State Street Corp | 3,228,557 | $1.4M | 0.0% | −615,115 |
| UBS Group AG | 2,997,073 | $1.3M | 0.0% | +711,190 |
| Pale Fire Capital SE | 2,511,478 | $1.1M | 0.1% | −204,850 |
| Marshall Wace, Llp | 2,354,193 | $1.0M | 0.0% | New |
| Congress Park Capital LLC | 2,016,447 | $860.6K | 0.2% | −2,016,290 |
| Richmond Brothers, Inc. | 1,792,319 | $765.0K | 0.4% | +355,614 |
| Vanguard Portfolio Management LLC | 1,580,510 | $674.9K | 0.0% | +271,198 |
| Aqr Capital Management LLC | 1,553,857 | $663.2K | 0.0% | +912,270 |
| Renaissance Technologies LLC | 1,506,900 | $643.1K | 0.0% | −211,400 |
| Vanguard Fiduciary Trust Co | 1,365,119 | $582.9K | 0.0% | +212,405 |
| Goldman Sachs Group Inc | 1,329,754 | $567.5K | 0.0% | +272,810 |
| Panagora Asset Management Inc | 1,281,796 | $547.1K | 0.0% | +319,291 |
| Northern Trust Corp | 1,223,480 | $522.2K | 0.0% | +50,955 |
| Charles Schwab Investment Management Inc | 1,217,463 | $519.6K | 0.0% | −158,904 |
| Qube Research & Technologies Ltd | 1,021,092 | $435.8K | 0.0% | +990,737 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 31, 2021 | Ashley Hinson ArenholzRepublican, House | Sale | $1,001 - $15,000 | +192.4% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How HERON THERAPEUTICS, INC. /DE/ is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARHERON THERAPEUTICS, INC. /DE/1
- CIK0000818033
- Employer ID (EIN)94-28755664
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address4242 Campus Point Court, Suite 200, San Diego, CA 921211
- Phone85825144001
- Shares outstanding189,852,307 as of Aug 5, 202610
- Public float$235.1M as of Jun 30, 20254
- AuditorWithumSmith+Brown, PC, Orlando, Florida PCAOB ID 100; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceFeb 1, 19941
- Filings1,513 in all: 4 (510), 8-K (336), SC 13G/A (137), 10-Q (96), SC 13G (50), 3 (43), DEF 14A (34), 10-K (30)1
All 53 form types
S-8 (25), SC 13D/A (25), 424B5 (17), 424B3 (16), UPLOAD (16), EFFECT (15), S-3 (14), PRE 14A (12), 4/A (11), CORRESP (11), DEFA14A (11), 11-K (9), 5 (9), ARS (9), 10-K/A (6), 8-K/A (6), S-3/A (6), D (5), CT ORDER (4), SCHEDULE 13G/A (4), 3/A (3), 8-A12B/A (3), S-1 (3), S-1/A (3), S-3ASR (3), SC 13D (3), 10-C (2), 10-Q/A (2), 424B2 (2), 424B4 (2), 8-A12B (2), FWP (2), POS AM (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 10-K405 (1), 25-NSE (1), 5/A (1), 8-A12G (1), CERTNAS (1), DEFR14A (1), NT 10-Q (1), PREC14A (1), PRER14A (1), RW (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 10, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Sep 29, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.01 per share | HRTX | Nasdaq |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks HERON THERAPEUTICS, INC. /DE/ names in Item 1A of its 10-K filed Feb 26, 2026: 54 risks under these headings, as written.4
- Risks Related to Our Business
- We are substantially dependent on the commercial success of our Products, and if these Products do not attain market acceptance by healthcare professionals and patients, our business and results of operations will suffer.
- If we are unable to develop and maintain sales, marketing and distribution capabilities or enter into agreements with third parties to sell and market our Products, our sales may be adversely affected.
- If we cannot maintain satisfactory pricing of our Products that is also acceptable to the U.S. government, insurance companies, managed care organizations and other payors, or arrange for favorable reimbursement policies, our product sales may be adversely affected and our future revenue may suffer.
- If we fail to comply with our reporting and payment obligations under U.S. governmental pricing and contracting programs, we could be subject to additional reimbursement requirements, penalties and fines, which could have a negative impact on our business, financial condition, and results of operations.
- If our suppliers or contract manufacturers are unable to manufacture in commercially viable quantities, we could face delays in our ability to commercialize our Products, our costs will increase and sales of our Products , may be severely hindered.
- We depend on third-party suppliers and contract manufacturers to manufacture our Products, and we expect to do the same for any future products that we develop; if our contract manufacturers do not perform as expected, our business could suffer.
- Certain of the components used in the manufacture of our Products are, or might be, sourced from a single vendor, and the loss or disruption of this vendor could significantly harm our business.
- Some of our suppliers may experience disruption to their respective supply chains due to the adverse events or conditions, including the effects of a pandemic or disease outbreak, the imposition of tariffs and other trade protective measures, rising geopolitical tensions, armed conflict, regulatory and policy changes or other factors, which could delay, prevent or impair our development or commercialization efforts.
- We have, or may have, significant inventory levels of drug products, and write-downs related to the impairment of those inventories may adversely impact or delay our profitability.
- It is difficult to predict commercial demand for our Products, and, if our estimates of demand are too low, it may adversely impact our ability to generate revenue and profits in the short term and our ability to establish and maintain a competitive position in the relevant markets where our Products are sold, or may be sold, in the future.
- We face intense competition from other companies developing products for the management of postoperative pain or the prevention of CINV and PONV, which may limit our ability to sell our Products.
The other 43 risks
- Our Products may face competition from lower-cost generic products offered by our competitors, which may limit our ability to sell our Products or require us to reduce our pricing.
- Our business and results of operations may suffer as a result of changes in our pricing or marketing strategies.
- Guidelines and recommendations published by various organizations could reduce the demand for or use of our Products.
- Because the results of preclinical studies and clinical trials are not necessarily predictive of future results, we can provide no assurances that our Products or product candidates will have favorable results in future studies or receive regulatory approval or expansion of approved indications.
- Interim, topline or preliminary data from our clinical trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Although the FDA might grant Fast Track, Breakthrough Therapy and Priority Review or similar designations to our Products and product candidates, there can be no assurance that any of our Products or product candidates that receive similar designations in the U.S. or in any other regulatory jurisdictions will receive regulatory approval any sooner than other Products or product candidates that do not have such designations, or at all.
- Our product platforms or product development efforts may not produce safe, efficacious or commercially viable products, and, if we are unable to develop new products, our business may suffer.
- We rely on third parties to conduct our preclinical testing and conduct our clinical trials, and their failure to perform their obligations in a timely and competent manner may delay development and commercialization of our Products and product candidates and our business could be substantially harmed.
- If we are unable to recruit and retain skilled employees, we may not be able to achieve our objectives.
- Our business strategy may include acquisitions of other businesses, products or product licenses. We may not be able to successfully manage such activities.
- Our business strategy may include entry into collaborative agreements. We may not be able to enter into collaborative agreements or may not be able to negotiate commercially acceptable terms for these agreements.
- Natural or man-made disasters, including severe weather, epidemics, pandemics, cyber attacks, acts of war or terrorism, armed conflict, federal workforce uncertainty, or resource shortages, could disrupt our investigational drug candidate development and approved drug commercialization efforts or have other negative consequences on our business and adversely affect results.
- Our potential international expansion of our business may expose us to new business, regulatory, political, operational, financial and economic risks associated with such expansion and could adversely affect our business, financial condition, results of operations and growth.
- Risks Related to Our Financial Condition
- We have a history of losses, we expect to generate losses in the near future, and we may never achieve or maintain profitability.
- Additional capital may be needed in the future to enable us to implement our business plan, and we may be unable to raise capital, which would force us to limit or cease our operations.
- Provisions contained in our debt instruments limit our ability to incur additional indebtedness.
- We could be exposed to significant product liability claims that could be time-consuming and costly to defend, divert management attention and adversely impact our ability to obtain and maintain insurance coverage.
- If any of our services providers are characterized as employees, we would be subject to employment and tax withholding liabilities and other additional costs.
- Changes to existing tax laws, or challenges to our tax positions could adversely affect our business and financial condition.
- The investment of our cash is subject to risks, which may cause losses or adversely affect the liquidity of these investments and our results of operations, liquidity and financial condition.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.
- Risks Related to Our Industry
- Failure to obtain regulatory approval in international jurisdictions would prevent our Products from being marketed abroad.
- If we fail to comply with continuing federal, state and foreign regulations with respect to our Products for which we obtain regulatory approval, we could lose our approvals to market drugs, and our business would be seriously harmed.
- The commercial use of our Products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our business.
- The pharmaceutical industry is subject to significant regulation and oversight pursuant to anti-kickback laws, false claims statutes and anti-corruption laws, which may result in significant additional expense and limit our ability to commercialize our Products. In addition, any failure to comply with these regulations could result in substantial fines or penalties.
- We may incur significant liability if it is determined that we are promoting the "off-label" use of drugs or promoting in a non-truthful and misleading way.
- Healthcare reform could increase our expenses and adversely affect the commercial success of our Products.
- Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
- Delays in, or suspensions and terminations of, clinical testing could increase our costs and delay our ability to obtain regulatory approval for, and commercialize, our product candidates.
- Our use of hazardous materials could subject us to liabilities, fines and sanctions.
- Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a negative impact on our business.
- We are and may become subject to stringent and evolving laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse business consequences.
- Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.
- Changes in government policies, laws, and regulations and with respect to the government workforce may have a negative impact on our business and the markets in which we operate.
- Risks Related to Our Intellectual Property
- If we are unable to adequately protect or enforce our intellectual property rights, we may lose valuable assets or incur costly litigation to protect our rights.
- We may be subject to claims that we have infringed on the intellectual property rights of others, and any litigation could force us to stop developing or selling potential products and could be costly, divert management attention and harm our business.
- We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
- Risks Related to Our Common Stock
- The price of our common stock has been and may continue to be volatile.
- Our certificate of incorporation, our bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.
- Future utilization of net operating loss carryforwards or research and development credit carryforwards may be impaired due to changes in ownership.
- Actions of activist stockholders could impact the pursuit of our business strategies, cause us to incur substantial costs, divert our management’s attention and resources, and adversely affect our business, results of operations, liquidity, financial condition, and the trading price of our common stock.
- If we identify a material weakness in our internal control over financial reporting, our ability to meet our reporting obligations and the trading price of our common stock could be negatively affected.
- Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the source of gain for our stockholders.
Legal proceedings
On June 14, 2022, the Company received a Paragraph IV notice of certification (the “Fresenius Kabi Notice”) from Fresenius Kabi advising that Fresenius Kabi had submitted an abbreviated new drug application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) seeking approval to manufacture, use or sell a generic version of CINVANTI in the U.S. prior to the expiration of U.S. Patent Nos.: 9,561,229; 9,808,465; 9,974,742; 9,974,793; 9,974,794; 10,500,208; 10,624,850; 10,953,018; and 11,173,118 (the “CINVANTI Patents”), which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). The Fresenius Kabi Notice alleges that the CINVANTI Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Fresenius Kabi’s ANDA.
On July 27, 2022, the Company filed a complaint for patent infringement of the CINVANTI Patents against Fresenius Kabi and a related entity in the U.S. District Court for the District of Delaware (the “Court”) in response to Fresenius Kabi’s ANDA filing. The complaint seeks, among other relief, equitable relief enjoining Fresenius Kabi from infringing the CINVANTI Patents. On May 15, 2024, the Court granted partial summary judgment of infringement for the Company and found no indefiniteness of U.S. Patent Nos. 9,561,229 and 9,974,794. On June 24, 2024, the parties commenced a four-day bench trial centered on Fresenius Kabi’s defense of obviousness of claims from U.S. Patent Nos. 9,561,229 and 9,974,794 that cover CINVANTI. Oral argument was held on August 29, 2024.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJohn Whelan, Chief executive officer
- 16
- 17
- 18
- 19SEC EDGARBarry D. Quart, President
- 20SEC EDGARJohn Poyhonen, President
- 21SEC EDGARIra Duarte, Chief financial officer
- 22
- 23
- 24SEC EDGARJohn Whelan, Chief financial officer
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37SEC EDGARThomas Cusack, Board member
- 38SEC EDGARMichael Kaseta, Board member
- 39SEC EDGARAdam Morgan, Board member
- 40SEC EDGARCraig A. Collard, Board member
- 41SEC EDGARKevin Kotler, Board member
- 42SEC EDGARSharmila Dissanaike, Board member
- 43SEC EDGARSusan Rodriguez, Board member
- 44SEC EDGARWaage Christian, Board member
- 45SEC EDGARCraig A. Johnson, Board member
- 46SEC EDGARKimberly Manhard, Board member
- 47SEC EDGARJohn Poyhonen, Board member
- 48SEC EDGARBarry D. Quart, Board member
- 49SEC EDGARKevin C. Tang, Board member
- 50SEC EDGARDennis L. Winger, Board member
- 51SEC EDGARGreg Turnbull, Board member
- 52SEC EDGARPeter Riepenhausen, Board member
- 53SEC EDGARRobert L. Zerbe Md., Board member
- 54SEC EDGARStephen A. Drury, Board member
- 55SEC EDGARToby Rosenblatt, Board member
- 56SEC EDGARPaul Goddard, Board member
- 57SEC EDGARArthur T. Taylor, Board member
- 58
- 59SEC EDGAREntered a material agreement
- 60
- 61SEC EDGARResults of operations
- 62SEC EDGARListing notice or transfer
- 63SEC EDGARShareholder vote
- 64SEC EDGAROther events
- 65SEC EDGARResults of operations
- 66SEC EDGARExecutive or director change
- 67SEC EDGARResults of operations
- 68SEC EDGARRegulation FD disclosure
- 69SEC EDGARResults of operations
- 70
- 71NasdaqNasdaq calendar
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92